Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Lymphoma × avelumab × Clear all

Phase

Status

Terminated 2 Completed 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 10 Neoplasms 9 Carcinoma, Transitional Cell 7 Neoplasm Metastasis 6 Colorectal Neoplasms 6 Urinary Bladder Neoplasms 5 Ovarian Neoplasms 5 Carcinoma, Renal Cell 4 Squamous Cell Carcinoma of Head and Neck 3 Recurrence 3 Glioblastoma 3 Carcinoma, Neuroendocrine 3 Stomach Neoplasms 2 Neuroendocrine Tumors 2 Kidney Neoplasms 2 Kidney Diseases 2 Glioma 2 Fallopian Tube Neoplasms 2 Carcinoma, Merkel Cell 2 Uterine Cervical Neoplasms 1 Urothelial Cancer 1 Urologic Neoplasms 1 Urethral Neoplasms 1 Ureteral Neoplasms 1 Triple Negative Breast Neoplasms 1 Testicular Neoplasms 1 Testicular Diseases 1 Sezary Syndrome 1 Sarcoma 1 Rectal Neoplasms 1

Interventions

Cyclophosphamide 256 Rituximab 234 Etoposide 145 Filgrastim 138 Vincristine 131 Doxorubicin 124 Prednisone 105 Radiotherapy 96 Cytarabine 96 Methotrexate 77 Peripheral Blood Stem Cell Transplantation 76 fludarabine phosphate 74 Melphalan 72 Busulfan 63 Dexamethasone 57 Granulocyte Colony-Stimulating Factor 49 Carmustine 47 fludarabine 46 Bortezomib 37 Ifosfamide 36 Whole-Body Irradiation 35 Tacrolimus 35 Gemcitabine 35 Leucovorin 34 Mycophenolic Acid 33 Antilymphocyte Serum 33 Cyclosporine 29 Methylprednisolone 28 Bendamustine Hydrochloride 28 sargramostim 27

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03046953 2024-07-16

AVAIL-T

University of Birmingham

Phase 2 Completed

35 enrolled 21 charts

Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡